We have previously shown that two antibodies, named A3 and A4, displaying low nM affinity for the receptor, are able to block ligand induced receptor phosphorylation and downstream AKT signaling in a variety of cancer cells and to efficiently inhibit tumor growth in xenograft models [32]. The gene discussed is AKT1; the disease is neoplasm.